Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | CNR1 | P21554 | 2/20 | 0.60 |
| ▸ | CNR2 | P34972 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.44 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5557339 | 0.80 | FES (0.61) | KMT2ACNR1CNR2MEN1HTT | |
| SCHEMBL5557503 | 0.77 | EPHX2 (0.53) | — | |
| SCHEMBL18263701 | 0.74 | KMT2A (0.71) | KMT2ACNR1CNR2MEN1ALDH1A1 | |
| SCHEMBL18263736 | 0.74 | KMT2A (0.71) | KMT2ACNR1CNR2MEN1ALDH1A1 | |
| SCHEMBL18271350 | 0.74 | KMT2A (0.71) | KMT2ACNR1CNR2MEN1ALDH1A1 | |
| SCHEMBL7663999 | 0.74 | CNR1 (0.73) | KMT2ACNR1CNR2MEN1CACNA2D1 | |
| SCHEMBL5557436 | 0.73 | CYP3A4 (0.48) | CYP3A4 | |
| SCHEMBL18263682 | 0.73 | CNR1 (0.69) | KMT2ACNR1CNR2MEN1ALDH1A1 | |
| SCHEMBL18270997 | 0.73 | CNR1 (0.69) | KMT2ACNR1CNR2MEN1ALDH1A1 | |
| SCHEMBL18263811 | 0.73 | CNR1 (0.69) | KMT2ACNR1CNR2MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1154998-B1 | INHIBITORS OF CELLULAR NIACINAMIDE MONONUCLEOTIDE FORMATION AND THEIR USE IN CANCER THERAPY | ASTELLAS DEUTSCHLAND GMBH (DE) | 2007-09-26 | — | — | EP | claimed |
| US-6506572-B2 | Inhibitor of niacinamide phosphoribosyl transferase (NAPRT) | KLINGE PHARMA GMBH (DE) | 2003-01-14 | — | — | US | claimed |
| JP-2002537380-A | — | — | 2002-11-05 | — | — | JP | claimed |
| US-20020160968-A1 | Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy | KLINGE PHARMA GMBH | 2002-10-31 | — | — | US | claimed |
| EP-1154998-A1 | INHIBITORS OF CELLULAR NIACINAMIDE MONONUCLEOTIDE FORMATION AND THEIR USE IN CANCER THERAPY | Klinge Pharma GmbH (DE) | 2001-11-21 | — | — | EP | claimed |
| WO-2000050399-A1 | INHIBITORS OF CELLULAR NIACINAMIDE MONONUCLEOTIDE FORMATION AND THEIR USE IN CANCER THERAPY | KLINGE PHARMA GMBH (DE) | 2000-08-31 | — | — | WO | claimed |
| EP-1031564-A1 | Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy | Klinge Pharma GmbH (DE) | 2000-08-30 | — | — | EP | claimed |
| EP-1154998-B1 | INHIBITORS OF CELLULAR NIACINAMIDE MONONUCLEOTIDE FORMATION AND THEIR USE IN CANCER THERAPY | ASTELLAS DEUTSCHLAND GMBH (DE) | 2007-09-26 | — | — | EP | disclosed |
| EP-1816124-A2 | Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy | Astellas Deutschland GmbH (DE) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160968-A1 | Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy | NAMPT, NAPRT, NNT | KMT2A 1425/4885CNR1 2724/4885CNR2 2062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.